{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:18:46Z","timestamp":1792102726612,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T00:00:00Z","timestamp":1696032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CSL Behring"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dermatomyositis is a rare disease characterized by progressive muscle weakness and skin rashes. Estimates of incidence and prevalence are fundamental measures in epidemiology, but few studies have been conducted on dermatomyositis. To address this knowledge gap, we conducted a population-based study to determine the contemporary incidence (between 2013 and 2019) and prevalence (2019) of adults living with dermatomyositis using administrative health data in Alberta, Canada. We also described disease-related medication use, as there are very few approved medications for the treatment of dermatomyositis, and no Canadian therapeutic guidelines. The average age- and sex-standardized annual incidence of dermatomyositis was 2.8\u20133.0 cases per 100,000 adults, and prevalence was 28.6 cases per 100,000 adults, which is greater than reported in other cohorts. Dermatomyositis-related medication use decreased from 73% in the first year to 46% in the eighth year after diagnosis. Glucocorticoids were the most commonly used drug class, often taken concurrently with various immunomodulatory agents; this medication use aligns with empirically-based recommendations and the few therapeutic guidelines for dermatomyositis. Considering that Alberta may have one of the highest rates of dermatomyositis among adults, further research on the burden of disease is warranted for planning within the health care system.<\/jats:p>","DOI":"10.1038\/s41598-023-43880-7","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T10:02:09Z","timestamp":1696068129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Mohammed","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen J. B.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai On","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Guigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Cohen Tervaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gniadecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Klarenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,30]]},"reference":[{"issue":"5","key":"43880_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/mus.24566","volume":"51","author":"AR Findlay","year":"2015","unstructured":"Findlay, A. R., Goyal, N. A. & Mozaffar, T. An overview of polymyositis and dermatomyositis. Muscle Nerve 51(5), 638\u2013656 (2015).","journal-title":"Muscle Nerve"},{"issue":"1","key":"43880_CR2","first-page":"29","volume":"8","author":"HM Babcock","year":"2016","unstructured":"Babcock, H. M. et al. The pathognomonicity of Gottron\u2019s sign. Can. J. Gen. Intern. Med. 8(1), 29 (2016).","journal-title":"Can. J. Gen. Intern. Med."},{"issue":"6","key":"43880_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","volume":"28","author":"H Sasaki","year":"2018","unstructured":"Sasaki, H. & Kohsaka, H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod. Rheumatol. 28(6), 913\u2013921 (2018).","journal-title":"Mod. Rheumatol."},{"issue":"2","key":"43880_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane, M. E., Waldman, R. & Lu, J. Dermatomyositis: Clinical features and pathogenesis. J. Am. Acad. Dermatol. 82(2), 267\u2013281 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"43880_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1756-185X.2010.01472.x","volume":"13","author":"S Cox","year":"2010","unstructured":"Cox, S. et al. Idiopathic inflammatory myopathies: Diagnostic criteria, classification and epidemiological features. Int. J. Rheum. Dis. 13(2), 117\u2013124 (2010).","journal-title":"Int. J. Rheum. Dis."},{"issue":"3","key":"43880_CR6","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1006\/clin.1997.4412","volume":"84","author":"DL Jacobson","year":"1997","unstructured":"Jacobson, D. L. et al. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84(3), 223\u2013243 (1997).","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"7","key":"43880_CR7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/ard.2008.093161","volume":"68","author":"S Bernatsky","year":"2009","unstructured":"Bernatsky, S. et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: Age, sex and regional differences. Ann. Rheum. Dis. 68(7), 1192\u20131196 (2009).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"43880_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Reeder","year":"2010","unstructured":"Reeder, M. J. et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: A population-based study in Olmsted County, Minnesota. Arch. Dermatol. 146(1), 26\u201330 (2010).","journal-title":"Arch. Dermatol."},{"issue":"3","key":"43880_CR9","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1756-185X.2011.01669.x","volume":"16","author":"JA Tan","year":"2013","unstructured":"Tan, J. A. et al. Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: A 30-year epidemiologic study of histology-proven cases. Int. J. Rheum. Dis. 16(3), 331\u2013338 (2013).","journal-title":"Int. J. Rheum. Dis."},{"key":"43880_CR10","unstructured":"Kronzer, V. L., et al. Incidence, prevalence, and mortality of dermatomyositis: A population-based cohort study. Arthritis Care Res (Hoboken) (2021)."},{"issue":"8","key":"43880_CR11","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/annrheumdis-2013-205127","volume":"74","author":"C Dobloug","year":"2015","unstructured":"Dobloug, C. et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann. Rheum. Dis. 74(8), 1551\u20131556 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"43880_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/mus.23302","volume":"45","author":"DE Furst","year":"2012","unstructured":"Furst, D. E. et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 45(5), 676\u2013683 (2012).","journal-title":"Muscle Nerve"},{"key":"43880_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1471-2474-13-103","volume":"13","author":"KE Smoyer-Tomic","year":"2012","unstructured":"Smoyer-Tomic, K. E., Amato, A. A. & Fernandes, A. W. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: An administrative claims analysis. BMC Musculoskelet. Disord. 13, 103 (2012).","journal-title":"BMC Musculoskelet. Disord."},{"issue":"1","key":"43880_CR14","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/ar4135","volume":"15","author":"E Linos","year":"2013","unstructured":"Linos, E. et al. Atherosclerotic cardiovascular disease and dermatomyositis: An analysis of the Nationwide Inpatient Sample survey. Arthritis Res. Ther. 15(1), R7 (2013).","journal-title":"Arthritis Res. Ther."},{"issue":"5, Part 1","key":"43880_CR15","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0190-9622(96)90037-7","volume":"34","author":"Guidelines\/Outcomes, C. and F. Task","year":"1996","unstructured":"Guidelines\/Outcomes, C. and F. Task. Guidelines of care for dermatomyositis. J. Am. Acad. Dermatol. 34(5, Part 1), 824\u2013829 (1996).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"43880_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/ddg.12909","volume":"14","author":"C Sunderk\u00f6tter","year":"2016","unstructured":"Sunderk\u00f6tter, C. et al. Guidelines on dermatomyositis\u2014Excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. JDDG Journal der Deutschen Dermatologischen Gesellschaft 14(3), 321\u2013338 (2016).","journal-title":"JDDG Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"1","key":"43880_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1521185","volume":"29","author":"H Kohsaka","year":"2019","unstructured":"Kohsaka, H. et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol 29(1), 1\u201319 (2019).","journal-title":"Mod Rheumatol"},{"issue":"5","key":"43880_CR18","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","volume":"61","author":"AGS Oldroyd","year":"2022","unstructured":"Oldroyd, A. G. S. et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology 61(5), 1760\u20131768 (2022).","journal-title":"Rheumatology"},{"key":"43880_CR19","unstructured":"Qudsiya, Z. & Waseem, M. Dermatomyositis, in StatPearls. 2023: Treasure Island (FL) ineligible companies. Disclosure: Muhammad Waseem declares no relevant financial relationships with ineligible companies."},{"issue":"11","key":"43880_CR20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/ard.2005.045690","volume":"65","author":"IM Bronner","year":"2006","unstructured":"Bronner, I. M. et al. Long-term outcome in polymyositis and dermatomyositis. Ann. Rheum. Dis. 65(11), 1456\u20131461 (2006).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"43880_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaad.2017.12.074","volume":"79","author":"DM Da Silva","year":"2018","unstructured":"Da Silva, D. M., Patel, B. & Werth, V. P. Dermatomyositis: A diagnostic dilemma. J. Am. Acad. Dermatol. 79(2), 371\u2013373 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"43880_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13023-022-02570-9","volume":"17","author":"T Namsrai","year":"2022","unstructured":"Namsrai, T. et al. Diagnostic delay of myositis: An integrated systematic review. Orphanet J. Rare Dis. 17(1), 420 (2022).","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"43880_CR23","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.101149","volume":"38","author":"S Bernatsky","year":"2011","unstructured":"Bernatsky, S., Linehan, T. & Hanly, J. G. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J. Rheumatol. 38(8), 1612\u20131616 (2011).","journal-title":"J. Rheumatol."},{"issue":"3","key":"43880_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10067-021-05939-6","volume":"41","author":"C Miyazaki","year":"2021","unstructured":"Miyazaki, C., Ishii, Y. & Stelmaszuk, N. M. Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: A real-world evidence study. Clin. Rheumatol. 41(3), 741\u2013755 (2021).","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"43880_CR25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaad.2019.05.105","volume":"82","author":"R Waldman","year":"2020","unstructured":"Waldman, R., DeWane, M. E. & Lu, J. Dermatomyositis: Diagnosis and treatment. J. Am. Acad. Dermatol. 82(2), 283\u2013296 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"43880_CR26","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/17512433.2017.1353910","volume":"10","author":"Z Griger","year":"2017","unstructured":"Griger, Z., Nagy-Vincze, M. & Danko, K. Pharmacological management of dermatomyositis. Expert Rev. Clin. Pharmacol. 10(10), 1109\u20131118 (2017).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"6","key":"43880_CR27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3109\/14397595.2015.1029239","volume":"25","author":"Y Yokoyama","year":"2015","unstructured":"Yokoyama, Y. et al. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod. Rheumatol. 25(6), 888\u2013892 (2015).","journal-title":"Mod. Rheumatol."},{"issue":"9596","key":"43880_CR28","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 370(9596), 1453\u20131457 (2007).","journal-title":"Lancet"},{"key":"43880_CR29","unstructured":"Jin, Y., et al. Comparison of Alberta population counts between the AHCIP registry and the 2006 census. Alberta Health and Wellness, Editor. 2009: Edmonton, Alberta, Canada."},{"key":"43880_CR30","unstructured":"Government of Alberta, Alberta population estimates - data tables. 2020: Her Majesty the Queen in right of Alberta, and agencies, boards, commissions or provincial corporations of Her Majesty."},{"key":"43880_CR31","unstructured":"du Plessis, V., et al. Definitions of rural. In Rural and Small Town Canada Analysis Bulletin. Statistics Canada (2001)."},{"issue":"5","key":"43880_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"M Charlson","year":"1987","unstructured":"Charlson, M. et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 40(5), 373\u2013383 (1987).","journal-title":"J. Chronic Dis."},{"key":"43880_CR33","unstructured":"Lix, L., et al. Cancer data linkage in Manitoba: Expanding the infrastructure for research. Manitoba Centre for Health Policy, January 2016: Winnipeg, MB (2016)."},{"key":"43880_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12911-015-0155-5","volume":"15","author":"M Tonelli","year":"2015","unstructured":"Tonelli, M. et al. Methods for identifying 30 chronic conditions: Application to administrative data. BMC Med. Inform. Decis. Mak. 15, 31 (2015).","journal-title":"BMC Med. Inform. Decis. Mak."},{"issue":"7","key":"43880_CR35","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S0828-282X(10)70412-8","volume":"26","author":"K Tu","year":"2010","unstructured":"Tu, K. et al. Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD). Can. J. Cardiol. 26(7), e225\u2013e228 (2010).","journal-title":"Can. J. Cardiol."},{"key":"43880_CR36","unstructured":"Canadian Stroke Best Practices Stroke Quality Advisory Committee. Quality of Stroke Care in Canada: Stroke Key Quality Indicators and Stroke Case Definitions. Heart and Stroke Foundation, Editor (2016)."},{"issue":"10","key":"43880_CR37","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/acr.24043","volume":"72","author":"BR England","year":"2020","unstructured":"England, B. R. et al. Performance of administrative algorithms to identify interstitial lung disease in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 72(10), 1392\u20131403 (2020).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"3","key":"43880_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.25251\/skin.5.3.19","volume":"5","author":"N Bowers","year":"2021","unstructured":"Bowers, N. & Huang, W. Treatment of refractory pruritus with dupilumab in a patient with dermatomyositis. SKIN J. Cutan. Med. 5(3), 319\u2013321 (2021).","journal-title":"SKIN J. Cutan. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43880-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43880-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43880-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:24:17Z","timestamp":1700285057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43880-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43880"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43880-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,30]]},"assertion":[{"value":"4 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: this research study was funded by CSL Behring awarded to MO. KM, KV, and SK are members of the Real-World Evidence Unit, an academic entity at the University of Alberta that conducts research including investigator-initiated industry-funded studies; KW and AG were previous members. JWCT and RG declare no competing interests. All authors of this study had complete autonomy over the content and submission of the manuscript, as well as the design and execution of the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16444"}}